Design of an Array to Evaluate Biomarkers of Response to Biological Treatments in Inflammatory Bowel Disease

Background: Inflammatory bowel disease (IBD) is defined as recurrent inflammatory bowel disorders, the most common of which are Crohn’s disease (CD) and ulcerative colitis (UC). Tumor necrosis factor inhibitors (anti-TNFs), primarily adalimumab (ADA), infliximab (IFX), ustekinumab (UST), and vedoliz...

Full description

Bibliographic Details

Published in:	Future Pharmacology
Main Authors:	Andrea Rodríguez-Lopez, Eva González-Iglesias, Jesús Novalbos, Susana Almenara, Francisco Abad-Santos
Format:	Article
Language:	English
Published:	MDPI AG 2025-07-01
Subjects:	inflammatory bowel disease Crohn’s disease ulcerative colitis adalimumab infliximab SNV
Online Access:	https://www.mdpi.com/2673-9879/5/3/39